Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

ALFApump System Post Marketing Surveillance Registry (2011-AAR-004)

This study is enrolling participants by invitation only.
Information provided by (Responsible Party):
Sequana Medical AG Identifier:
First received: February 9, 2012
Last updated: August 10, 2016
Last verified: August 2016
This is a post market surveillance registry to monitor the safety and performance of the ALFApump system.

Liver Cirrhosis
Refractory Ascites
Malignant Ascites

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 2 Years
Official Title: ALFApump System Post Marketing Surveillance Registry, In Support of the Following Indication: Automated Removal of Excess Peritoneal Fluid Into the Urinary Bladder in Patients With Cirrhosis or Malignancy, With Persistent or Refractory Ascites

Resource links provided by NLM:

Further study details as provided by Sequana Medical AG:

Primary Outcome Measures:
  • Safety [ Time Frame: 24 months ]
    To monitor the safety of the ALFApump System

Secondary Outcome Measures:
  • clinical performance [ Time Frame: 24 months ]
    To monitor clinical performance of the ALFApump System

  • clinical impact [ Time Frame: 24 months ]
    To monitor the clinical impact of the ALFApump System

  • usability [ Time Frame: 1 month ]
    To assess the usability of the ALFApump System

Estimated Enrollment: 200
Study Start Date: June 2012
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The Registry will include 200 patients implanted after market approval at up to 25 centres, in patients with liver cirrhosis or malignancy, with persistent or refractory ascites.

Inclusion Criteria:

  • Refractory or recurrent ascites and liver cirrhosis or malignancy
  • written informed consent

Exclusion Criteria:

  • < 18 years
  • pregnant
  • not able to use the Smart charger
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01532427

Uniklinik Dresden
Dresden, Germany
Klinikum der Johann Wolfgang Goethe Universität
Frankfurt, Germany
Universitätsklinikum des Saarlandes
Homburg/Saar, Germany, 66421
Universitätsklinikum Jena
Jena, Germany, 07747
St Georg Klinik
Leipzig, Germany, 04129
Universitätsklinikum Leipzig, AöR
Leipzig, Germany
Medizinische Klinik, Universitätsmedizin Mannheim
Mannheim, Germany
Uniklinik Würzburg
Würzburg, Germany
Hosptial Universitari Vall d'Hebron
Barcelona, Spain
Bern, Switzerland, 3010
University Clinic of Geneva (HUG)
Geneva, Switzerland
United Kingdom
The London Clinic, The liver centre
London, United Kingdom
Freeman Hospital Newcastle on Tyne
Newcastle on Tyne, United Kingdom
Sponsors and Collaborators
Sequana Medical AG
Principal Investigator: Andrea De Gottardi, Privatdozent University Hospital Inselspital, Berne
  More Information

Responsible Party: Sequana Medical AG Identifier: NCT01532427     History of Changes
Other Study ID Numbers: 2011-AAR-004
Study First Received: February 9, 2012
Last Updated: August 10, 2016

Additional relevant MeSH terms:
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases processed this record on April 27, 2017